[go: up one dir, main page]

US20160198759A1 - E-cigarette or vaping fluid - Google Patents

E-cigarette or vaping fluid Download PDF

Info

Publication number
US20160198759A1
US20160198759A1 US14/984,774 US201514984774A US2016198759A1 US 20160198759 A1 US20160198759 A1 US 20160198759A1 US 201514984774 A US201514984774 A US 201514984774A US 2016198759 A1 US2016198759 A1 US 2016198759A1
Authority
US
United States
Prior art keywords
fluid
concentration
volume
cyclodextrin
ingredients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/984,774
Other languages
English (en)
Inventor
Shyam Kuntawala
Lawrence Moy
Ashish Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zip LLC
Original Assignee
Zip LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zip LLC filed Critical Zip LLC
Priority to US14/984,774 priority Critical patent/US20160198759A1/en
Priority to PCT/US2016/013248 priority patent/WO2016115250A1/fr
Publication of US20160198759A1 publication Critical patent/US20160198759A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/10—Chemical features of tobacco products or tobacco substitutes
    • A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/10—Chemical features of tobacco products or tobacco substitutes
    • A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
    • A24B15/167—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes in liquid or vaporisable form, e.g. liquid compositions for electronic cigarettes
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/281—Treatment of tobacco products or tobacco substitutes by chemical substances the action of the chemical substances being delayed
    • A24B15/283—Treatment of tobacco products or tobacco substitutes by chemical substances the action of the chemical substances being delayed by encapsulation of the chemical substances
    • A24B15/284—Treatment of tobacco products or tobacco substitutes by chemical substances the action of the chemical substances being delayed by encapsulation of the chemical substances the additive being bound to a host by chemical, electrical or like forces, e.g. use of precursors, inclusion complexes
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
    • A24B15/308—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances vitamins
    • A24F47/008—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/84—Valerianaceae (Valerian family), e.g. valerian
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
    • A24F40/10—Devices using liquid inhalable precursors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy

Definitions

  • the current invention is in the area of e-cigarettes and “vaping” and concerns an improved non-nicotine fluid for e-cigarette devices.
  • Smoking has a long history in human cultures. When plant materials are burned various organic chemicals that are constituents of the plant vaporize and attach themselves to the smoke particles. At the same time heat and combustion break down constituent organic chemicals and produce new chemicals all of which are present in the vapor state and/or attach themselves to the smoke particles. When the smoke is inhaled, the particles come into contact with the surface of lung cells and the chemicals absorbed to the particles transfer to the lung cells and eventually are transferred into the circulatory system. Because of the extremely large surface area of the lung, smoking is an extremely effective route for administering active compounds. Because plants contain a wide variety of secondary products inhaling the smoke delivers these products to the human body. The physiological results can be stimulation, depression or even hallucination depending on what type of plant is burned to produce the smoke.
  • tobacco smoking is highly addictive as in the case of nicotine in tobacco smoke.
  • tobacco smoking was once considered to be a benign or even healthful pastime, it is now considered to be a health hazard.
  • tobacco smoking is major cause of lung as well as other cancers in smokers as well as those exposed to “second hand” smoke.
  • tobacco smoking is major cause of lung as well as other cancers in smokers as well as those exposed to “second hand” smoke.
  • Electro cigarettes have been developed as a safer alternative to smoking tobacco.
  • a mechanism reduces a liquid (“e-cigarette fluid,” “e-fluid” or “vaping fluid”) into a smoke-like mixture of air and tiny droplets (an aerosol) which material is then inhaled. Any active constituents in the vaping fluid are then absorbed by the lungs like real smoke.
  • e-cigarettes do not produce smoke, other terms have been developed to describe using the devices.
  • vaping One such term that is gaining popularity is “vaping.”
  • one does not smoke an e-cigarette—one “vapes” it.
  • E-cigarettes are thought to be safer than smoking tobacco because nothing is actually burned in an e-cigarette.
  • the most common type of e-cigarette has a heating element which vaporizes the e-fluid to create an aerosol. Less commonly there is mechanical production of the aerosol. For example, some devices use a piezoelectric diaphragm which vibrates at ultrasonic speeds to directly form an aerosol from the e-fluid rather like a cool-mist humidifier.
  • e-fluids contain nicotine (approximately 0.04M-0.12M) so that vaping an e-cigarette can act as a substitute for smoking tobacco by delivering nicotine to the user.
  • nicotine e-cigarettes As smoking cessation devices. The idea is that the users transition to the e-cigarettes and then use e-fluids with diminishing levels of nicotine until the user's nicotine addiction is overcome.
  • many users alternate between “real” cigarettes and e-cigarettes so the usefulness of vaping e-cigarettes as an aid to smoking cessation is somewhat questionable. Certainly, the e-cigarette avoids the dangers of secondhand tobacco smoke.
  • vaping fluids can be obtained by combining a variety of active ingredients with the hydrophilic solvents typical of such fluids.
  • the active ingredients are chosen depending on the desired effects of using the fluid.
  • methylzanthines such as caffeine can be used to provide an energy boost product.
  • Energy boost formulae can also contain taurine, cyanocobalamin, carnitine, guarana, and ginseng.
  • Relaxation/sleep formulae can include chamomile, valerian, kava and other active ingredients.
  • Appetite suppressant formulae can contain hoodia, yerba mate, caralluma and lecithin.
  • scents/flavors and colors can also be included. It is preferred to used natural plant extracts to impart colors.
  • Cyclodextrin is included to enhance absorption of the active ingredients as well as to limit any tendency of the inhaled aerosol to cause irritation.
  • e-fluids contain water and one or more hydrophilic solvent such as glycerol, propylene glycol and/or polyethylene glycol.
  • the hydrophilic solvent is important for the production of aerosols by a heat source. When a water solution of these solvents contacts a heat source, the water rapidly vaporizes leaving behind an aerosol of hydrophilic solvent particles which contain the other ingredients that were dissolved in the original e-fluid and/or the other ingredients are present as tiny particles.
  • the “other ingredients” include flavors, scents and additives intended to enhance the efficacy of the other ingredients.
  • the ingredients must be carried into the user's lungs. This generally occurs because the ingredients are bound to or dissolved in the aerosol particles.
  • the aerosol particles may not always be of optimum size so that they are filtered out by lung structures before there is a chance for the active ingredients to be properly absorbed. In other cases the aerosol particles are somewhat irritating to the user's throat and other tissues.
  • cyclodextrins are useful for sequestering hydrophobic molecules and for forming droplets in a nebulizer.
  • cyclodextrins also promote aerosol formation with the heating elements of common e-cigarettes (as well as with the spray jets of nebulizers). More importantly, the addition of sufficient cyclodextrin to e-fluid enhances the absorption and bioavailability of any active ingredients while at the same time reducing any tendency towards irritation caused by the aerosol.
  • the cyclodextrin molecules form a somewhat conical structure—that is, a hollow cylinder having a smaller opening at one end than the other.
  • the cyclodextrin molecule in solution has an interior that is more hydrophobic than its exterior (i.e., the exterior is relatively hydrophilic).
  • the molecule to be sequestered must be at least partially hydrophobic and of dimensions to fit within the cyclodextrin ring.
  • Active ingredients such as methylxanthines and nicotine are of the right size for sequestration and are essentially hydrophobic at physiological and acid pHs.
  • cyclodextrin is affected by the active ingredient as well as the other ingredients in the e-fluid formula. Both ⁇ and ⁇ cyclodextrin have a water solubility that is approximately an order of magnitude higher than that of ⁇ cyclodextrin. Therefore, if it is desired to use a relatively high level of active ingredient, a and ⁇ cyclodextrin are preferred. Otherwise, ⁇ cyclodextrin operates adequately.
  • a methylxanthine alkaloid such as caffeine is combined with taurine which has beneficial biological as well as surfactant properties.
  • methylxanthine alkaloids improve energy and provide a feeling of well-being.
  • Taurine is a natural amino acid derivative that has an anti-anxiety effect as well as many health benefits.
  • taurine has surfactant properties and aids in the dispersion of insoluble ingredients.
  • Caffeine is effective in e-fluids of 0.01M to 0.15M. Much below this concentration range, there is little discernible effect whereas at much higher concentrations, the caffeine effect can be excessive. Currently, a concentration of 0.05M is preferred.
  • Taurine has a wide effective range of at least 0.01M to 0.1M; currently 0.015M is preferred.
  • cyanocobalamin vitamin B12
  • This water soluble vitamin is important for many cellular functions and seems to potentiate the effects of caffeine and taurine.
  • the cyanocobalamin has a red-magenta color and can be used as the sole coloring agent or other colors may be added as desired. This has been tested at concentrations between 0.01% and 0.1%; currently 0.083% (weight by volume) is preferred.
  • Other common methylxanthines such as theophylline or theobromine can be substituted or used in conjunction with caffeine.
  • Energy Boost ingredients can be used either alone or in conjunction with the methylxanthines.
  • green tea extracts can be employed not only as a source of caffeine and theophylline but also for beneficial antioxidants (and to impart a flavor).
  • Extracts of guarana can be used to supply caffeine as well as other beneficial natural ingredients.
  • Extracts of Ginkgo biloba can be used to supply antioxidants Extracts of ginseng ( Panax species) are also effective when combined with cyclodextrins.
  • carnitine is effective in energy formulae. These ingredients are generally used at concentration of about 0.5% by weight or less.
  • Caffeine, other methylxanthines and taurine can be stabilized as metal complexes (zinc, magnesium and/or sodium) and/or cyclodextrin complexes.
  • Metal complexes are formed by adding a molar excess of a water soluble salt of the desired metal. Cyclodextrin complexes form best with a molar excess of cyclodextrin. It has been found that a 2-3 fold molar excess works well although cyclodextrin is effective in the range of 0.5 to 5.0 molar ratio of cyclodextrin to active ingredient. Cyclodextrin is used preferable but can be used with the metal complex as well. That is, the required concentration of both metal and cyclodextrin can be used.
  • “Relaxation/sleep” formulae are also useful.
  • ingredients such as extracts of chamomile ( Matricaria chamomilla and/or Chamaemelum nobile ), extracts of kava ( Piper methysticum ), extracts of valerian ( Valeriana officinalis ), L-tryptophan and/or melatonin are used in place of the “energy” ingredients. Again these ingredients are used in the 0.5% by weight or lower concentration range.
  • the main vehicle is an approximately 50% aqueous solution of high boiling point hydrophilic solvent. It is not essential that the fluid be precisely 50% water. Typically either glycerol and/or propylene glycol are used as hydrophilic solvents. This translates to a 5.4M glycerol or a 6.6M propylene glycol solution. Tests suggest that a solution being at least about 2M of either of these solvents (or a combination thereof) is adequate. Using excess hydrophilic solvent increases both the cost and viscosity of the product. The hydrophilic solvents increase the solubility of the active ingredients and act as particle formers when the e-cigarette mechanism boils away much of the water. Without these solvents aerosol formation would be much less efficient.
  • the inactive ingredients include a variety of flavors and/or scents. Actually, these additives are primarily scents because the human sense of taste is primarily limited to sweet, salty, sour, bitter and umami. What we perceive of as “orange” flavor or taste is actually orange scent combined with a taste of sweet and sour.
  • the glycerol and propylene glycol components of the vehicle have an actual sweet taste that can be detected by most users. Depending on the pH of the vehicle there may also be a slight sour (low pH) taste. If active ingredients such as caffeine or nicotine are present at sufficiently high concentrations, there may also be an actual discernible bitter taste. Useful scents are practically unlimited. Traditionally, menthol and mint-related scents were used in tobacco cigarettes.
  • mint-related scents are useful in e-fluid.
  • fruit flavors i.e., orange and banana
  • scents such as vanilla.
  • the preferred “flavors” are green apple, vanilla cupcake, blueberry, and mango.
  • various herbal, musky and other scents may also be appropriate. Generally, these are used at very low concentrations. Generally, under 0.1% by volume. Many of the plant extracts mentioned above also provide a unique flavor/scent.
  • the ingredients are mixed, the pH adjusted to 6.5 and heated to 60° C. to ensure that the scent/flavor is properly dispersed.
  • the ingredients are mixed, the pH adjusted to 6.5 and heated to 60° C. to ensure that the scent/flavor is properly dispersed.
  • the ingredients are mixed, the pH adjusted to 6.5 and heated to 60° C. to ensure that the scent/flavor is properly dispersed.
  • the ingredients are mixed, the pH adjusted to 6.5 and heated to 60° C. to ensure that the scent/flavor is properly dispersed.
  • the ingredients are mixed, the pH adjusted to 6.5 and heated to 60° C. to ensure that the scent/flavor is properly dispersed.
  • the ingredients are mixed, the pH adjusted to 6.5 and heated to 60° C. to ensure that the scent/flavor is properly dispersed.
  • the ingredients are mixed, the pH adjusted to 6.5 and heated to 60° C. to ensure that the scent/flavor is properly dispersed.
  • the ingredients are mixed, the pH adjusted to 6.5 and heated to 60° C. to ensure that the scent/flavor is properly dispersed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
US14/984,774 2015-01-13 2015-12-30 E-cigarette or vaping fluid Abandoned US20160198759A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US14/984,774 US20160198759A1 (en) 2015-01-13 2015-12-30 E-cigarette or vaping fluid
PCT/US2016/013248 WO2016115250A1 (fr) 2015-01-13 2016-01-13 Cigarette électronique ou fluide de vapotage amélioré

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562102894P 2015-01-13 2015-01-13
US14/984,774 US20160198759A1 (en) 2015-01-13 2015-12-30 E-cigarette or vaping fluid

Publications (1)

Publication Number Publication Date
US20160198759A1 true US20160198759A1 (en) 2016-07-14

Family

ID=56366526

Family Applications (1)

Application Number Title Priority Date Filing Date
US14/984,774 Abandoned US20160198759A1 (en) 2015-01-13 2015-12-30 E-cigarette or vaping fluid

Country Status (2)

Country Link
US (1) US20160198759A1 (fr)
WO (1) WO2016115250A1 (fr)

Cited By (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9770055B2 (en) 2015-05-15 2017-09-26 Lunatech, Llc Vaporizable material handling for electronic vapor device
US9888723B2 (en) 2015-05-15 2018-02-13 Lunatech, Llc Hybrid vapor delivery system utilizing nebulized and non-nebulized elements
US9888725B2 (en) 2015-07-28 2018-02-13 Lunatech, Llc Inhalation puff counter gauge and display system
US9933790B2 (en) 2015-06-15 2018-04-03 Lunatech, Llc Peer-to-peer air analysis and treatment
US9936737B2 (en) 2015-10-28 2018-04-10 Lunatech, Llc Methods and systems for a dual function vapor device
USD825102S1 (en) 2016-07-28 2018-08-07 Juul Labs, Inc. Vaporizer device with cartridge
US10039320B2 (en) 2015-05-14 2018-08-07 Lunatech, Llc Multi-chambered vaporizer and blend control
US10042369B2 (en) 2015-06-16 2018-08-07 Lunatech, Llc Vapor device for filtering and testing material
US10045567B2 (en) 2013-12-23 2018-08-14 Juul Labs, Inc. Vaporization device systems and methods
US10045568B2 (en) 2013-12-23 2018-08-14 Juul Labs, Inc. Vaporization device systems and methods
US10060639B2 (en) 2015-06-11 2018-08-28 Lunatech, Llc Air analyzer and treatment apparatus
US10058130B2 (en) 2013-12-23 2018-08-28 Juul Labs, Inc. Cartridge for use with a vaporizer device
US10065138B2 (en) 2015-06-17 2018-09-04 Lunatech, Llc Remote controllable air treatment apparatus
US10076139B2 (en) 2013-12-23 2018-09-18 Juul Labs, Inc. Vaporizer apparatus
US10088463B2 (en) 2015-06-11 2018-10-02 Lunatech, Llc Calibrating electronic vapor device
US10104915B2 (en) 2013-12-23 2018-10-23 Juul Labs, Inc. Securely attaching cartridges for vaporizer devices
US10111470B2 (en) 2013-12-23 2018-10-30 Juul Labs, Inc. Vaporizer apparatus
US20180338905A1 (en) * 2017-05-26 2018-11-29 Inhale Health, LLC Bioavailable aerosolized supplement formulations
USD836541S1 (en) 2016-06-23 2018-12-25 Pax Labs, Inc. Charging device
US10215430B2 (en) 2015-06-15 2019-02-26 Lunatech, Llc Electronic vapor and analysis with HVAC integration
US10215429B2 (en) 2015-06-15 2019-02-26 Lunatech, Llc Localized air sensing and treatment
USD842536S1 (en) 2016-07-28 2019-03-05 Juul Labs, Inc. Vaporizer cartridge
US10244793B2 (en) 2005-07-19 2019-04-02 Juul Labs, Inc. Devices for vaporization of a substance
US10279934B2 (en) 2013-03-15 2019-05-07 Juul Labs, Inc. Fillable vaporizer cartridge and method of filling
WO2019086858A1 (fr) * 2017-11-01 2019-05-09 British American Tobacco (Investments) Limited Formulation aérosolisable
WO2019086857A1 (fr) * 2017-11-01 2019-05-09 Nicoventures Holdings Limited Formulation vaporisable aromatisée
USD849996S1 (en) 2016-06-16 2019-05-28 Pax Labs, Inc. Vaporizer cartridge
USD851830S1 (en) 2016-06-23 2019-06-18 Pax Labs, Inc. Combined vaporizer tamp and pick tool
US10405582B2 (en) 2016-03-10 2019-09-10 Pax Labs, Inc. Vaporization device with lip sensing
US10512282B2 (en) 2014-12-05 2019-12-24 Juul Labs, Inc. Calibrated dose control
WO2020089634A1 (fr) * 2018-11-01 2020-05-07 Nicoventures Trading Limited Formulation aérosolisable
WO2020089641A1 (fr) * 2018-11-01 2020-05-07 Nicoventures Trading Limited Formulation aérosolisable
WO2020089638A1 (fr) * 2018-11-01 2020-05-07 Nicoventures Trading Limited Formulation en aérosol
WO2020089639A1 (fr) * 2018-11-01 2020-05-07 Nicoventures Trading Limited Formulation en aérosol
WO2020089635A1 (fr) * 2018-11-01 2020-05-07 Nicoventures Trading Limited Formulation aérosolisable
USD887632S1 (en) 2017-09-14 2020-06-16 Pax Labs, Inc. Vaporizer cartridge
WO2020205676A1 (fr) * 2019-03-29 2020-10-08 V Rush Vapes LLC Composition de suppléments pour athlétisme et entraînement physique, procédé de production et procédé d'administration pulmonaire de celle-ci
US10865001B2 (en) 2016-02-11 2020-12-15 Juul Labs, Inc. Fillable vaporizer cartridge and method of filling
WO2021042269A1 (fr) * 2019-09-03 2021-03-11 深圳雾芯科技有限公司 Liquide pour cigarette électronique
CN112911950A (zh) * 2018-11-01 2021-06-04 尼科创业贸易有限公司 可气雾化配制品
KR20210074308A (ko) * 2018-11-01 2021-06-21 니코벤처스 트레이딩 리미티드 에어로졸화 가능한 포뮬레이션
KR20210075107A (ko) * 2018-11-01 2021-06-22 니코벤처스 트레이딩 리미티드 에어로졸화 가능한 포뮬레이션
EP3873241A1 (fr) * 2018-11-01 2021-09-08 Nicoventures Trading Limited Formulation aérosolisable
WO2022049512A1 (fr) * 2020-09-03 2022-03-10 Rai Strategic Holdings, Inc. Formulation aérosolisable
CN114299688A (zh) * 2021-12-29 2022-04-08 张璇燕 一种基于电子烟雾检测的烟油成分识别方法及系统
RU2785541C2 (ru) * 2018-11-01 2022-12-08 Никовенчерс Трейдинг Лимитед Превращенная в аэрозоль композиция
US11553734B2 (en) 2018-11-08 2023-01-17 Juul Labs, Inc. Cartridges for vaporizer devices
JP2023538482A (ja) * 2020-07-17 2023-09-08 ニコベンチャーズ トレーディング リミテッド 消耗品
US12114689B2 (en) 2018-11-01 2024-10-15 Nicoventures Trading Limited Gel and crystalline powder

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110558605B (zh) * 2019-09-27 2021-07-06 深圳雾芯科技有限公司 电子烟液
GB2586301B (en) 2020-04-07 2021-08-25 Splash Tm Gmbh Stable-Foam inhalation Device and Cartridge

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030159702A1 (en) * 2002-01-21 2003-08-28 Lindell Katarina E.A. Formulation and use manufacture thereof
US20030171408A1 (en) * 2002-03-11 2003-09-11 Caplan Jay L. Therapeutic method of delivering a medicament to avoid irritating effects on membranes of user
ES2592882T3 (es) * 2008-10-14 2016-12-02 Mcneil Ab Forma de dosificación intra-oral de múltiples porciones y uso de la misma

Cited By (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10244793B2 (en) 2005-07-19 2019-04-02 Juul Labs, Inc. Devices for vaporization of a substance
US10638792B2 (en) 2013-03-15 2020-05-05 Juul Labs, Inc. Securely attaching cartridges for vaporizer devices
US10279934B2 (en) 2013-03-15 2019-05-07 Juul Labs, Inc. Fillable vaporizer cartridge and method of filling
US10070669B2 (en) 2013-12-23 2018-09-11 Juul Labs, Inc. Cartridge for use with a vaporizer device
US10058130B2 (en) 2013-12-23 2018-08-28 Juul Labs, Inc. Cartridge for use with a vaporizer device
US10201190B2 (en) 2013-12-23 2019-02-12 Juul Labs, Inc. Cartridge for use with a vaporizer device
US10117466B2 (en) 2013-12-23 2018-11-06 Juul Labs, Inc. Vaporization device systems and methods
US10667560B2 (en) 2013-12-23 2020-06-02 Juul Labs, Inc. Vaporizer apparatus
US10045567B2 (en) 2013-12-23 2018-08-14 Juul Labs, Inc. Vaporization device systems and methods
US10045568B2 (en) 2013-12-23 2018-08-14 Juul Labs, Inc. Vaporization device systems and methods
US11752283B2 (en) 2013-12-23 2023-09-12 Juul Labs, Inc. Vaporization device systems and methods
US10058124B2 (en) 2013-12-23 2018-08-28 Juul Labs, Inc. Vaporization device systems and methods
US10912331B2 (en) 2013-12-23 2021-02-09 Juul Labs, Inc. Vaporization device systems and methods
US10058129B2 (en) 2013-12-23 2018-08-28 Juul Labs, Inc. Vaporization device systems and methods
US10264823B2 (en) 2013-12-23 2019-04-23 Juul Labs, Inc. Vaporization device systems and methods
US10159282B2 (en) 2013-12-23 2018-12-25 Juul Labs, Inc. Cartridge for use with a vaporizer device
US10076139B2 (en) 2013-12-23 2018-09-18 Juul Labs, Inc. Vaporizer apparatus
US10701975B2 (en) 2013-12-23 2020-07-07 Juul Labs, Inc. Vaporization device systems and methods
US10104915B2 (en) 2013-12-23 2018-10-23 Juul Labs, Inc. Securely attaching cartridges for vaporizer devices
US10111470B2 (en) 2013-12-23 2018-10-30 Juul Labs, Inc. Vaporizer apparatus
US10117465B2 (en) 2013-12-23 2018-11-06 Juul Labs, Inc. Vaporization device systems and methods
US10512282B2 (en) 2014-12-05 2019-12-24 Juul Labs, Inc. Calibrated dose control
US10039320B2 (en) 2015-05-14 2018-08-07 Lunatech, Llc Multi-chambered vaporizer and blend control
US9770055B2 (en) 2015-05-15 2017-09-26 Lunatech, Llc Vaporizable material handling for electronic vapor device
US9888723B2 (en) 2015-05-15 2018-02-13 Lunatech, Llc Hybrid vapor delivery system utilizing nebulized and non-nebulized elements
US10088463B2 (en) 2015-06-11 2018-10-02 Lunatech, Llc Calibrating electronic vapor device
US10060639B2 (en) 2015-06-11 2018-08-28 Lunatech, Llc Air analyzer and treatment apparatus
US10215430B2 (en) 2015-06-15 2019-02-26 Lunatech, Llc Electronic vapor and analysis with HVAC integration
US10215429B2 (en) 2015-06-15 2019-02-26 Lunatech, Llc Localized air sensing and treatment
US9933790B2 (en) 2015-06-15 2018-04-03 Lunatech, Llc Peer-to-peer air analysis and treatment
US10042369B2 (en) 2015-06-16 2018-08-07 Lunatech, Llc Vapor device for filtering and testing material
US10065138B2 (en) 2015-06-17 2018-09-04 Lunatech, Llc Remote controllable air treatment apparatus
US9888725B2 (en) 2015-07-28 2018-02-13 Lunatech, Llc Inhalation puff counter gauge and display system
US9936737B2 (en) 2015-10-28 2018-04-10 Lunatech, Llc Methods and systems for a dual function vapor device
US10865001B2 (en) 2016-02-11 2020-12-15 Juul Labs, Inc. Fillable vaporizer cartridge and method of filling
US10405582B2 (en) 2016-03-10 2019-09-10 Pax Labs, Inc. Vaporization device with lip sensing
USD849996S1 (en) 2016-06-16 2019-05-28 Pax Labs, Inc. Vaporizer cartridge
USD913583S1 (en) 2016-06-16 2021-03-16 Pax Labs, Inc. Vaporizer device
USD929036S1 (en) 2016-06-16 2021-08-24 Pax Labs, Inc. Vaporizer cartridge and device assembly
USD851830S1 (en) 2016-06-23 2019-06-18 Pax Labs, Inc. Combined vaporizer tamp and pick tool
USD836541S1 (en) 2016-06-23 2018-12-25 Pax Labs, Inc. Charging device
USD825102S1 (en) 2016-07-28 2018-08-07 Juul Labs, Inc. Vaporizer device with cartridge
USD842536S1 (en) 2016-07-28 2019-03-05 Juul Labs, Inc. Vaporizer cartridge
EP3630119A4 (fr) * 2017-05-26 2020-12-30 Inhale Health LLC Formulations de suppléments sous forme d'aérosol biodisponibles et méthodes associées
US20180338905A1 (en) * 2017-05-26 2018-11-29 Inhale Health, LLC Bioavailable aerosolized supplement formulations
USD887632S1 (en) 2017-09-14 2020-06-16 Pax Labs, Inc. Vaporizer cartridge
USD927061S1 (en) 2017-09-14 2021-08-03 Pax Labs, Inc. Vaporizer cartridge
KR20230113841A (ko) * 2017-11-01 2023-08-01 니코벤처스 트레이딩 리미티드 에어로졸화 가능한 제제
JP2021500890A (ja) * 2017-11-01 2021-01-14 ニコベンチャーズ トレーディング リミテッド 加香された気化性配合物
CN111542233A (zh) * 2017-11-01 2020-08-14 尼科创业贸易有限公司 可气溶胶化制剂
CN111629607A (zh) * 2017-11-01 2020-09-04 尼科创业贸易有限公司 调味的可汽化制剂
KR102444095B1 (ko) * 2017-11-01 2022-09-15 니코벤처스 트레이딩 리미티드 가향 기화성 제제
RU2736854C1 (ru) * 2017-11-01 2020-11-20 Никовенчерс Трейдинг Лимитед Способная образовывать аэрозоль композиция
KR102559988B1 (ko) * 2017-11-01 2023-07-25 니코벤처스 트레이딩 리미티드 에어로졸화 가능한 제제
KR20200060478A (ko) * 2017-11-01 2020-05-29 니코벤처스 트레이딩 리미티드 가향 기화성 제제
KR20200056459A (ko) 2017-11-01 2020-05-22 니코벤처스 트레이딩 리미티드 에어로졸화 가능한 제제
EP3703518B1 (fr) 2017-11-01 2024-07-31 Nicoventures Trading Limited Formulation aérosolisable
JP2021500888A (ja) * 2017-11-01 2021-01-14 ニコベンチャーズ トレーディング リミテッド エアロゾル化可能な配合物
JP7041261B2 (ja) 2017-11-01 2022-03-23 ニコベンチャーズ トレーディング リミテッド 加香された気化性配合物
KR102771014B1 (ko) * 2017-11-01 2025-02-19 니코벤처스 트레이딩 리미티드 에어로졸화 가능한 제제
RU2745353C1 (ru) * 2017-11-01 2021-03-24 Никовенчерс Трейдинг Лимитед Ароматизированная испаряемая композиция
WO2019086857A1 (fr) * 2017-11-01 2019-05-09 Nicoventures Holdings Limited Formulation vaporisable aromatisée
WO2019086858A1 (fr) * 2017-11-01 2019-05-09 British American Tobacco (Investments) Limited Formulation aérosolisable
US20210177040A1 (en) * 2017-11-01 2021-06-17 Nicoventures Trading Limited Aerosolizable formulation
CN112911950A (zh) * 2018-11-01 2021-06-04 尼科创业贸易有限公司 可气雾化配制品
WO2020089635A1 (fr) * 2018-11-01 2020-05-07 Nicoventures Trading Limited Formulation aérosolisable
CN113038842A (zh) * 2018-11-01 2021-06-25 尼科创业贸易有限公司 可气雾化配制品
CN113056208A (zh) * 2018-11-01 2021-06-29 尼科创业贸易有限公司 可气雾化配制品
KR20210080404A (ko) * 2018-11-01 2021-06-30 니코벤처스 트레이딩 리미티드 에어로졸화된 포뮬레이션
KR20210080403A (ko) * 2018-11-01 2021-06-30 니코벤처스 트레이딩 리미티드 에어로졸화된 포뮬레이션
KR20210080406A (ko) * 2018-11-01 2021-06-30 니코벤처스 트레이딩 리미티드 에어로졸화 가능한 포뮬레이션
KR20210080402A (ko) * 2018-11-01 2021-06-30 니코벤처스 트레이딩 리미티드 에어로졸화 가능한 포뮬레이션
CN113163841A (zh) * 2018-11-01 2021-07-23 尼科创业贸易有限公司 可气雾化配制品
CN113163840A (zh) * 2018-11-01 2021-07-23 尼科创业贸易有限公司 气雾化配制品
CN113163842A (zh) * 2018-11-01 2021-07-23 尼科创业贸易有限公司 可气雾化配制品
KR20210074308A (ko) * 2018-11-01 2021-06-21 니코벤처스 트레이딩 리미티드 에어로졸화 가능한 포뮬레이션
CN113226067A (zh) * 2018-11-01 2021-08-06 尼科创业贸易有限公司 气雾化配制品
KR20210070333A (ko) * 2018-11-01 2021-06-14 니코벤처스 트레이딩 리미티드 에어로졸화 가능한 포뮬레이션
EP3873241A1 (fr) * 2018-11-01 2021-09-08 Nicoventures Trading Limited Formulation aérosolisable
US20210368852A1 (en) * 2018-11-01 2021-12-02 Nicoventures Trading Limited Aerosolised formulation
US20210386111A1 (en) * 2018-11-01 2021-12-16 Nicoventures Trading Limited Aerosolisable formulation
RU2764202C1 (ru) * 2018-11-01 2022-01-14 Никовенчерс Трейдинг Лимитед Превращенная в аэрозоль композиция
JP2022505851A (ja) * 2018-11-01 2022-01-14 ニコベンチャーズ トレーディング リミテッド エアロゾル化可能な配合物
JP2022506107A (ja) * 2018-11-01 2022-01-17 ニコベンチャーズ トレーディング リミテッド エアロゾル化可能な配合物
JP2022506076A (ja) * 2018-11-01 2022-01-17 ニコベンチャーズ トレーディング リミテッド エアロゾル化された配合物
JP2022506067A (ja) * 2018-11-01 2022-01-17 ニコベンチャーズ トレーディング リミテッド エアロゾル化可能な配合物
AU2019371080B2 (en) * 2018-11-01 2022-07-14 Nicoventures Trading Limited Aerosolisable formulation
AU2019372223B2 (en) * 2018-11-01 2022-07-14 Nicoventures Trading Limited Aerosolised formulation
AU2019370810B2 (en) * 2018-11-01 2022-11-10 Nicoventures Trading Limited Aerosolised formulation
AU2019370809B2 (en) * 2018-11-01 2022-12-01 Nicoventures Trading Limited Aerosolisable formulation
RU2785541C2 (ru) * 2018-11-01 2022-12-08 Никовенчерс Трейдинг Лимитед Превращенная в аэрозоль композиция
RU2785974C2 (ru) * 2018-11-01 2022-12-15 Никовенчерс Трейдинг Лимитед Способная образовывать аэрозоль композиция
US12478090B2 (en) 2018-11-01 2025-11-25 Nicoventures Trading Limited Aerosolizable formulation
US20230165299A1 (en) * 2018-11-01 2023-06-01 Nicoventures Trading Limited Aerosolisable formulation
US20230180818A1 (en) * 2018-11-01 2023-06-15 Nicoventures Trading Limited Aerosolised formulation
KR20210075107A (ko) * 2018-11-01 2021-06-22 니코벤처스 트레이딩 리미티드 에어로졸화 가능한 포뮬레이션
WO2020089639A1 (fr) * 2018-11-01 2020-05-07 Nicoventures Trading Limited Formulation en aérosol
JP2023120433A (ja) * 2018-11-01 2023-08-29 ニコベンチャーズ トレーディング リミテッド エアロゾル化された配合物
US12419339B2 (en) * 2018-11-01 2025-09-23 Nicoventures Trading Limited Aerosolized formulation
JP7703445B2 (ja) 2018-11-01 2025-07-07 ニコベンチャーズ トレーディング リミテッド エアロゾル化可能な配合物
KR102782830B1 (ko) * 2018-11-01 2025-03-14 니코벤처스 트레이딩 리미티드 에어로졸화 가능한 포뮬레이션
WO2020089634A1 (fr) * 2018-11-01 2020-05-07 Nicoventures Trading Limited Formulation aérosolisable
US12193471B2 (en) * 2018-11-01 2025-01-14 Nicoventures Trading Limited Aerosolizable formulation
WO2020089638A1 (fr) * 2018-11-01 2020-05-07 Nicoventures Trading Limited Formulation en aérosol
RU2806111C2 (ru) * 2018-11-01 2023-10-26 Никовенчерс Трейдинг Лимитед Способная образовывать аэрозоль композиция
KR102652876B1 (ko) 2018-11-01 2024-03-28 니코벤처스 트레이딩 리미티드 에어로졸화 가능한 포뮬레이션
KR102732972B1 (ko) * 2018-11-01 2024-11-20 니코벤처스 트레이딩 리미티드 에어로졸화 가능한 포뮬레이션
EP4324341A3 (fr) * 2018-11-01 2024-04-17 Nicoventures Trading Limited Formulation aérosolisable
IL282461B1 (en) * 2018-11-01 2024-07-01 Nicoventures Trading Ltd Aerosolisable formulation
KR102684583B1 (ko) * 2018-11-01 2024-07-11 니코벤처스 트레이딩 리미티드 에어로졸화 가능한 포뮬레이션
KR102684661B1 (ko) 2018-11-01 2024-07-11 니코벤처스 트레이딩 리미티드 에어로졸화된 포뮬레이션
KR102684663B1 (ko) * 2018-11-01 2024-07-11 니코벤처스 트레이딩 리미티드 에어로졸화된 포뮬레이션
KR102684717B1 (ko) * 2018-11-01 2024-07-11 니코벤처스 트레이딩 리미티드 에어로졸화 가능한 포뮬레이션
WO2020089641A1 (fr) * 2018-11-01 2020-05-07 Nicoventures Trading Limited Formulation aérosolisable
US12114689B2 (en) 2018-11-01 2024-10-15 Nicoventures Trading Limited Gel and crystalline powder
IL282461B2 (en) * 2018-11-01 2024-11-01 Nicoventures Trading Ltd Aerosolisable formulation
US11553734B2 (en) 2018-11-08 2023-01-17 Juul Labs, Inc. Cartridges for vaporizer devices
WO2020205676A1 (fr) * 2019-03-29 2020-10-08 V Rush Vapes LLC Composition de suppléments pour athlétisme et entraînement physique, procédé de production et procédé d'administration pulmonaire de celle-ci
WO2021042269A1 (fr) * 2019-09-03 2021-03-11 深圳雾芯科技有限公司 Liquide pour cigarette électronique
JP2023538482A (ja) * 2020-07-17 2023-09-08 ニコベンチャーズ トレーディング リミテッド 消耗品
AU2021335797B2 (en) * 2020-09-03 2024-03-28 Rai Strategic Holdings, Inc. Aerosolisable formulation
JP2023538723A (ja) * 2020-09-03 2023-09-11 アール・エイ・アイ・ストラテジック・ホールディングス・インコーポレイテッド エアロゾル化可能配合物
WO2022049512A1 (fr) * 2020-09-03 2022-03-10 Rai Strategic Holdings, Inc. Formulation aérosolisable
JP7724843B2 (ja) 2020-09-03 2025-08-18 アール・エイ・アイ・ストラテジック・ホールディングス・インコーポレイテッド エアロゾル化可能配合物
CN114299688A (zh) * 2021-12-29 2022-04-08 张璇燕 一种基于电子烟雾检测的烟油成分识别方法及系统

Also Published As

Publication number Publication date
WO2016115250A1 (fr) 2016-07-21

Similar Documents

Publication Publication Date Title
US20160198759A1 (en) E-cigarette or vaping fluid
US20240215633A1 (en) Inhalable compositions comprising caffeine, methods of use and an apparatus for using the same
CA2691571C (fr) Composition inhalable
KR101956318B1 (ko) 흡연의 화학적 감각을 모사하기 위한 장치 및 방법
EP2941135B1 (fr) Substitut de tabac
WO2016133890A1 (fr) Compositions pour cigarettes électroniques
KR20100028182A (ko) 전자 담배용 니코틴 수용액
ES2984536T3 (es) Formulación aerosolizable
CN104585862B (zh) 一种无甜腻感电子烟烟液
RS64142B1 (sr) Kompozicija
CN104970445B (zh) 一种缓释型气雾口香烟
US20200261439A1 (en) Nicotine formulation for active mesh nebulizer
KR20120083648A (ko) 다마스콘 함유 금연보조제 조성물
ES3036472T3 (en) Agents for modulating the sensory impact of tobacco or herbal smoke
KR20110023949A (ko) 금연보조담배용 가연성 무화용액
CN105054281A (zh) 一种气雾型口香烟
JP2024531502A (ja) 噴霧投与用の医用液体組成物
US20220022521A1 (en) New tobacco substitutes
JP2002281939A (ja) 生薬食料製品
JP2025537767A (ja) エアロゾル化可能な配合物のための消耗品
Novikova et al. Are E-Cigarettes Safer than Cigarette Smoking?
KR20250172135A (ko) 각성 및 활력 증진을 위한 흡입용 조성물 및 이를 포함하는 흡입용 조성물 공급 장치
CN101356994A (zh) 健康香烟

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION